Abstract
The most widely used therapy modality for the treatment of bladder cancer (BC) is based on the intravesical administration of Bacillus Calmette-Gueri (BCG) associated with transurethral resection. The anti-tumor effects of BCG start by triggering a systemic immune response involving both humoral and cellular components through the activation of Toll-like receptors (TLR) agonists, providin…